Busca avançada
Ano de início
Entree
(Referência obtida automaticamente do Web of Science, por meio da informação sobre o financiamento pela FAPESP e o número do processo correspondente, incluída na publicação pelos autores.)

Protease-activated receptor 1 as a potential therapeutic target for COVID-19

Texto completo
Autor(es):
Rovai, Emanuel S. [1] ; Alves, Tomaz [2] ; Holzhausen, Marinella [2]
Número total de Autores: 3
Afiliação do(s) autor(es):
[1] Univ Taubate, Dept Dent, BR-12010490 Taubate, SP - Brazil
[2] Univ Sao Paulo, Sch Dent, Dept Stomatol, Div Periodont, BR-05508000 Sao Paulo - Brazil
Número total de Afiliações: 2
Tipo de documento: Artigo de Revisão
Fonte: Experimental Biology and Medicine; v. 246, n. 6, p. 688-694, MAR 2021.
Citações Web of Science: 1
Resumo

Acute respiratory disease caused by a novel coronavirus (SARS-CoV-2) has spread all over the world, since its discovery in 2019, Wuhan, China. This disease is called COVID-19 and already killed over 1 million people worldwide. The clinical symptoms include fever, dry cough, dyspnea, headache, dizziness, generalized weakness, vomiting, and diarrhea. Unfortunately, so far, there is no validated vaccine, and its management consists mainly of supportive care. Venous thrombosis and pulmonary embolism are highly prevalent in patients suffering from severe COVID-19. In fact, a prothrombotic state seems to be present in most fatal cases of the disease. SARS-CoV-2 leads to the production of proinflammatory cytokines, causing immune-mediated tissue damage, disruption of the endothelial barrier, and uncontrolled thrombogenesis. Thrombin is the key regulator of coagulation and fibrin formation. In severe COVID-19, a dysfunctional of physiological anticoagulant mechanisms leads to a progressive increase of thrombin activity, which is associated with acute respiratory distress syndrome development and a poor prognosis. Protease-activated receptor type 1 (PAR1) is the main thrombin receptor and may represent an essential link between coagulation and inflammation in the pathophysiology of COVID-19. In this review, we discuss the potential role of PAR1 inhibition and regulation in COVID-19 treatment. (AU)

Processo FAPESP: 18/13818-5 - Efeito da ativação do Receptor Ativado por Protease do tipo 1 (PAR1) sobre a atividade osteogênica em membranas de células-tronco do ligamento periodontal humano. ensaio in vivo
Beneficiário:Tomaz Alves da Silva Neto
Linha de fomento: Bolsas no Brasil - Mestrado
Processo FAPESP: 19/14846-5 - Avaliação do perfil proteômico salivar em pacientes diabéticos tipo 2 com periodontite
Beneficiário:Emanuel da Silva Rovai
Linha de fomento: Auxílio à Pesquisa - Regular
Processo FAPESP: 17/23158-0 - Efeito da ativação do receptor ativado por protease do tipo 1 (par1) sobre a atividade osteogênica em membranas de células-tronco do ligamento periodontal humano
Beneficiário:Marinella Holzhausen Caldeira
Linha de fomento: Auxílio à Pesquisa - Regular